Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377419 | 0.92 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL10151731 | 0.90 | PPARD (0.69) | PPARDPPARA | |
| SCHEMBL377517 | 0.90 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL7021782 | 0.90 | PPARD (1.00) | PPARDPPARA | |
| SCHEMBL377188 | 0.88 | PPARD (0.87) | PPARDPPARA | |
| SCHEMBL19509806 | 0.88 | PPARD (0.87) | PPARDPPARA | |
| SCHEMBL377898 | 0.88 | PPARD (0.77) | PPARDPPARA | |
| SCHEMBL7018578 | 0.88 | PPARD (0.77) | PPARDPPARA | |
| SCHEMBL377897 | 0.88 | PPARD (0.77) | PPARDPPARA | |
| SCHEMBL377742 | 0.87 | PPARD (1.00) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152295-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | METABOLEX INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010045361-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | METABOLEX, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152295-A1 | METHODS OF REDUCING SMALL, DENSE LDL PARTICLES | LDLR, APOB, HDLBP | PPARD 345/4885PPARA 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.